ARCH

ARCH Motorcycle partners with Hexagon to craft bespoke high-performance cruisers with production motorcycle quality

Retrieved on: 
Thursday, March 14, 2024
Partnership, Motorcycle, AS1, Computer-aided design, Arch Motorcycle, Hexagon, 3D, Engineering, CAD, Software, ARCH, 3D printing

The partnership is geared to help ARCH expand its commitment to producing bespoke motorcycles by fully digitizing quality processes throughout engineering and manufacturing with state-of-the-art measurement technologies.

Key Points: 
  • The partnership is geared to help ARCH expand its commitment to producing bespoke motorcycles by fully digitizing quality processes throughout engineering and manufacturing with state-of-the-art measurement technologies.
  • The technology will also help ARCH Motorcycle create tailored ergonomic motorcycle designs that incorporate individual customer specifications for shocks, seats, handlebars, foot controls, and overall fit.
  • Our goal is to integrate Hexagon's latest metrology technologies throughout our manufacturing and quality control processes to achieve meticulous finish and uncompromising quality for every ARCH motorcycle.
  • This immediate access to accurate 3D measurement data is intended to help produce the one-of-a-kind experiences and production motorcycle quality that customers want."

ARCH Motorcycle partners with Hexagon to craft bespoke high-performance cruisers with production motorcycle quality

Retrieved on: 
Thursday, March 14, 2024
Partnership, Motorcycle, AS1, Computer-aided design, Arch Motorcycle, Hexagon, 3D, Engineering, CAD, Software, ARCH, 3D printing

The partnership is geared to help ARCH expand its commitment to producing bespoke motorcycles by fully digitizing quality processes throughout engineering and manufacturing with state-of-the-art measurement technologies.

Key Points: 
  • The partnership is geared to help ARCH expand its commitment to producing bespoke motorcycles by fully digitizing quality processes throughout engineering and manufacturing with state-of-the-art measurement technologies.
  • The technology will also help ARCH Motorcycle create tailored ergonomic motorcycle designs that incorporate individual customer specifications for shocks, seats, handlebars, foot controls, and overall fit.
  • Our goal is to integrate Hexagon's latest metrology technologies throughout our manufacturing and quality control processes to achieve meticulous finish and uncompromising quality for every ARCH motorcycle.
  • This immediate access to accurate 3D measurement data is intended to help produce the one-of-a-kind experiences and production motorcycle quality that customers want."

Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, Health, Pharmaceutical, Physical Therapy, Cardiology, BMD, Exercise, Principal investigator, Network, Myopathy, Edgewise, Conference, Muscular Dystrophy Association, University, Therapy, ARCH, Associate professor, University of Florida, Poster, Trade, Convention, MDA, Physiology, Episcopal conference, University of Copenhagen

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on EDG-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference.

Key Points: 
  • Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on EDG-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference.
  • The conference will take place at the Hilton Orlando in Orlando, FL from March 3-6, 2024.
  • Posters will be showcased during the Networking & Poster Reception in the Exhibit Hall on Monday, March 4, 2024, from 6 – 8 PM ET.
  • The Edgewise presentation and posters will be available on the Edgewise website when they are presented.

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, February 22, 2024
Health, Other Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Muscular dystrophy, Research, American Heart Association, Education, R9, MESA, Ageing, Fast Track, NSAA, McArdle, DUNE, Myopathy, Therapy, WMS, LYNX, ODD, Safety, Biomarker, Pharmacokinetics, HCM, Clinical trial, Caregiver, FOX, FDA, Muscle contraction, Engagement, Duchenne muscular dystrophy, ARCH, Administration, Patient, Disease, Pharmaceutical industry

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year of 2023 and recent business highlights.

Key Points: 
  • Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year of 2023 and recent business highlights.
  • “In 2023, we made tremendous progress advancing our novel muscle-targeted therapeutics in the clinic,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise.
  • Research and development (R&D) expenses were $27.7 million for the fourth quarter of 2023, compared to $23.8 million for the immediately preceding quarter.
  • General and Administrative (G&A) expenses were $6.2 million for the fourth quarter of 2023, compared to $5.7 million for the immediately preceding quarter.

Matter Neuroscience Secures $26M in Funding to Cure Unhappiness

Retrieved on: 
Tuesday, February 27, 2024
Neuroimaging, DEPT, Happiness, Diagnosis, Anxiety, Mental health, Interventional radiology, Emotion, Research, Biomedical engineering, Professor, Collaborative Fund, Capitalism, Polaris Partners, Capital, Imaging, Neurology, Risk, Trial of the century, Health, Human Brain Project, Medical imaging, Brain mapping, ARCH, Bayer, Bouchon, Maastricht University, Biological engineering, Psychiatry, Science, Magnetic resonance, ARCH Venture Partners, Good Worldwide, Addiction, Brain, Depression

NEW YORK, Feb. 27, 2024 /PRNewswire/ -- Matter Neuroscience, the company working to unlock a deeper understanding of happiness and well-being by providing people with personalized insights into their brain chemistry emerges from stealth mode today. Matter announced it has received $26 million in funding, initial funding seeded by Polaris Partners and a more recent round co-led by ARCH Venture Partners, Polaris Partners, and Exor Ventures, and joined by Collaborative Fund and others. With this backing, Matter will bolster its efforts to pioneer solutions that address the unhappiness epidemic by transforming our understanding and management of mental well-being.

Key Points: 
  • With this backing, Matter will bolster its efforts to pioneer solutions that address the unhappiness epidemic by transforming our understanding and management of mental well-being.
  • Together with its collaboration partners, Matter Neuroscience will initiate three more clinical studies in 2024.
  • Matter also offers users access to educational materials and a lecture series on the neuroscience of happiness.
  • Matter Neuroscience was co-founded in 2019 with Ben Goldhirsh of GOOD Worldwide and the Goldhirsh Foundation, and Chris Shiflett of Faculty and Brooklyn Beta.

Proniras Corporation Secures New Series B Financing and Names New Board Members to Support Phase 1 Study of Novel Treatment for Opiate Withdrawal

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, ARCH Venture Partners, Senior, Corporation, GSK plc, MedImmune, Takeda Pharmaceutical Company, Knowledge, Eli Lilly and Company, Opioid, WRF, VBI Vaccines, AstraZeneca, Acquisition, Development, Epilepsy, Public, Growth, General counsel, Vilya, Corporate development, Patient, Venture round, LP, Research, Trial of the century, ARCH, Therapy, DSM-IV codes, Series

PRN-001-01 (tezampanel) is a novel small molecule compound that will be the first parenteral therapeutic to be evaluated for the treatment of symptoms associated with opiate withdrawal in a Phase 1 clinical study.

Key Points: 
  • PRN-001-01 (tezampanel) is a novel small molecule compound that will be the first parenteral therapeutic to be evaluated for the treatment of symptoms associated with opiate withdrawal in a Phase 1 clinical study.
  • In conjunction with the Series B financing, Proniras has appointed Steven Gillis, Ph.D., as Chairman and Atul Saran as an independent member to the Company’s Board of Directors.
  • "Their wealth of knowledge and industry experience will be instrumental in guiding Proniras through its next phase of growth.
  • We look forward to their leadership and contributions as we continue to advance Proniras through the next stages of product development."

iSpecimen and TriMetis Life Sciences Announce Strategic Partnership to Help Transform Tissue-Based Research

Retrieved on: 
Tuesday, January 23, 2024
Pathology, Marie Cassidy, Patient, Research, Hospital, TCAP, Partnership, ARCH, AI, Workflow, Ecosystem, Risk, Quality control, Laboratory, Automation, Medical imaging

This agreement aims to establish a strategic partnership between iSpecimen and TriMetis, providing opportunities for iSpecimen, its suppliers and customers to utilize technology solutions from TriMetis.

Key Points: 
  • This agreement aims to establish a strategic partnership between iSpecimen and TriMetis, providing opportunities for iSpecimen, its suppliers and customers to utilize technology solutions from TriMetis.
  • Focusing initially on a substantial subset of solid tumor types utilizing TriMetis’ Computer-Assisted Pathology (TCAP) Quality Control AI, the partnership will help standardize and enhance tissue sample evaluation.
  • Ms. Curley continued, “For both iSpecimen and TriMetis, the focus is first and foremost on establishing best practices for quality control and assurance.
  • This partnership will focus on simplifying and standardizing these processes by utilizing TriMetis’ digital AI services and tapping into iSpecimen’s global network.

Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 9, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, McArdle, Ageing, MESA, Therapy, Muscular dystrophy, ARCH, FOX, HCM, LYNX, LGMD, Myopathy, Conference, Safety, FDA, Webcast, Biomarker, Food and Drug Administration, Exercise, Pharmacokinetics, Pharmaceutical industry

Ahead of the presentation, the Company highlighted its 2023 accomplishments and announced its anticipated key milestones for 2024.

Key Points: 
  • Ahead of the presentation, the Company highlighted its 2023 accomplishments and announced its anticipated key milestones for 2024.
  • MESA will provide continued access to EDG-5506 treatment to study participants who were previously enrolled in Edgewise studies.
  • Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
    Edgewise will webcast its presentation today from the J.P. Morgan 42nd Annual Healthcare Conference at 10:30 am PT (1:30 pm ET).
  • A replay of the webcast will be available on Edgewise’s website for a limited time following the conference.

Moonwalk Biosciences Launches with $57 Million in Financing to Advance a New Class of Precision Epigenetic Medicines

Retrieved on: 
Thursday, January 4, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Biology, Epigenome, Entrepreneurship, Broad Institute, Howard Hughes Medical Institute, Gene editing, Moonwalk, Multimedia, Software, MIT, DRS, Disease, DNA, CBO, AI, ARCH Venture Partners, ARCH, Engineering, Gene, Harvard University, Khosla Ventures, Genome, GV

The financing will support continued advancement of Moonwalk’s epigenetic profiling and engineering technology platform and progress its pipeline of epigenetic therapeutics towards the clinic.

Key Points: 
  • The financing will support continued advancement of Moonwalk’s epigenetic profiling and engineering technology platform and progress its pipeline of epigenetic therapeutics towards the clinic.
  • View the full release here: https://www.businesswire.com/news/home/20240104793936/en/
    Moonwalk Biosciences founding team (from left to right): Alex Aravanis, CEO, Justin Valley, COO, Elaine Cheung, CBO, Arash Jamshidi, President & CTO.
  • Moonwalk is the first company that couples an epigenetic discovery platform with precise engineering – opening up the epigenome as a new target space for complex diseases.
  • We look forward to what new innovations Moonwalk can advance in epigenetic engineering,” said Robert Nelsen, Managing Director and Co-Founder, ARCH Venture Partners.

Top Tier Impact Investment Panel & Dinner: Accelerating the Energy Transition and Decarbonisation during COP28

Retrieved on: 
Tuesday, December 19, 2023
COP28, Energy transition, ESG, Doctor of Philosophy, Role, Heart, ARCH, TTI, DoubleTree, Investment, Climate, Emirates Nuclear Energy Corporation

The evening commenced with a welcome by İlkay Demirdag , TTI Head of Global Events, followed by insightful opening remarks by Alessa Berg , Founder and CEO of Top Tier Impact.

Key Points: 
  • The evening commenced with a welcome by İlkay Demirdag , TTI Head of Global Events, followed by insightful opening remarks by Alessa Berg , Founder and CEO of Top Tier Impact.
  • The keynote presentations from David Scott ( Emirates Nuclear Energy Corporation) and Sweta Chakraborty, PhD ( We Don't Have Time , North America CEO) set a thoughtful tone for the discussions ahead in the energy space.
  • The heart of the event unfolded through two substantive panel discussions:
    "Accelerating the Energy Transition" - Moderated by Alessa Berg, this panel delved into the pioneering efforts of Tarkan Ozballar, EnerGreen CEO, in utilizing blockchain for renewable energy investment.
  • Top Tier Impact (TTI) was founded in 2019 by Alessa Berg to create more synergies in the climate and ESG space.